The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: Pooled analysis of five randomized, placebo-controlled trials

Menopause

Volumn 23, Issue 4, 2016, Pages 376-382

  Black, Denise ^a   Messig, Michael ^b   Yu, Ching Ray ^b   Assaf, Annlouise R ^b   Komm, Barry S ^b   Mirkin, Sebastian ^b   Boucher, Matthieu ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b PFIZER INC   (United States)

Author keywords

Bazedoxifene; Hormone therapy; Menopause; Selective estrogen receptor modulators; Weight gain

Indexed keywords

BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; BAZEDOXIFENE; CONJUGATED ESTROGEN; INDOLE DERIVATIVE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; BODY MASS; BODY WEIGHT; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; POST HOC ANALYSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERUS; WEIGHT GAIN; DRUG EFFECTS; HOT FLASHES; MIDDLE AGED;

ADULT; AGED; BODY MASS INDEX; BODY WEIGHT; DOUBLE-BLIND METHOD; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84951325564     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000541     Document Type: Conference Paper

References (37)

1. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005;118(suppl 12B):14-24.
2. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25-54.
3. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am 2011;38:489-501.
4. Sturdee DW, Pines A, Archer DF, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-320.
5. Strothmann A, Schneider HP. Hormone therapy: the European women's perspective. Climacteric 2003;6:337-346.
6. Buhling KJ, Daniels B, Studnitz FS, Eulenburg C, Mueck AO. Attitude of German women towards hormone therapy: results of a lay survey. Gynecol Endocrinol 2013;29:460-464.
7. Genazzani AR, Gambacciani M. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Gynecol Endocrinol 2006;22:145-150.
8. Kritz-Silverstein D, Barrett-Connor E. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA 1996;275:46-49.
9. Sayegh RA, Kelly L, Wurtman J, Deitch A, Chelmow D. Impact of hormone replacement therapy on the body mass and fat compositions of menopausal women: a cross-sectional study. Menopause 1999;6:312-315.
10. Jensen LB, Vestergaard P, Hermann AP, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 2003;18:333-342.
11. Yuksel H, Odabasi AR, Demircan S, Koseoglu K, Kizilkaya K, Onur E. Effects of postmenopausal hormone replacement therapy on body fat composition. Gynecol Endocrinol 2007;23:99-104.
12. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9.
13. Chen Z, Bassford T, Green SB, et al. Postmenopausal hormone therapy and body composition-a substudy of the estrogen plus progestin trial of the Women's Health Initiative. Am J Clin Nutr 2005;82:651-656.
14. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149: 6084-6091.
15. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-1024.
16. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
17. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-1124.
18. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo-and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postme-nopausal women. Menopause 2010;17:281-289.
19. Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013;16:338-346.
20. Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99:E189-E198.
21. Fontana R, Della TS, Meda C, Longo A, Eva C, Maggi AC. Estrogen replacement therapy regulation of energy metabolism in female mouse hypothalamus. Endocrinology 2014;155:2213-2221.
22. Kim JH, Meyers MS, Khuder SS, et al. Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. Mol Metab 2014;3:177-190.
23. Barrera J, Chambliss KL, Ahmed M, et al. Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis and type 2 diabetes in mice without impacting the reproductive tract. Am J Physiol Endocrinol Metab 2014;307:E345-E354.
24. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Pro-gestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 2005;96:95-108.
25. Li C, Samsioe G, Wilaman K, et al. Effects of norethisterone acetate addition to estradiol in long term HRT. Maturitas 2000;36:139-152.
26. Samsioe G, Hruska J. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results. Climacteric 2010;13:34-44.
27. Tugrul S, Yildirim G, Pekin O, Uslu H, Kutlu T, Eren S. Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects. Arch Gynecol Obstet 2007;275:335-339.
28. Portman DJ, Kaunitz AM, Kazempour K, Mekonnen H, Bhaskar S, Lippman J. Effects of low-dose paroxetine 7.5mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause 2014;21:1082-1090.
29. Gabapentin [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2013.
30. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc; 2014.
31. Clonidine hydrochloride [package insert]. Elizabeth, NJ: BluePoint Laboratories; 2014.
32. Fluoxetine [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2014.
33. Celexa [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc; 2013.
34. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014;21:924-932.
35. Herber-Gast GC, Mishra GD, van der Schouw YT, Brown WJ, Dobson AJ. Risk factors for night sweats and hot flushes in midlife: results from a prospective cohort study. Menopause 2013;20:953-959.
36. Da Fonseca AM, Bagnoli VR, Souza MA, et al. Impact of age and body mass on the intensity of menopausal symptoms in 5968 Brazilian women. Gynecol Endocrinol 2013;29:116-118.
37. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006;96:1226-1235.